Opening soon. Stay in the loop

goodmorrowJoin the opening list

BPC-157, explained.

Body Protection Compound 157. Research, safety questions, and treatment context.

Updated Clinical review pending · Educational draft

The form

More than one catalog form

The routine

A reliable wellness schedule has not been established in strong human trials.

The evidence

Mostly animal research · limited human reports

Forms listed in a June 2025 catalog. Current availability and individual instructions need confirmation.

Legal status
Backed by FDA advisers, awaiting final rule

FDA advisers voted 8 to 6 on July 23, 2026 to allow compounding. Pharmacies can't make it until the FDA finalizes that decision.

At Goodmorrow
Waitlist open

What it is

BPC-157 is a chain of 15 amino acids based on a protein found in human stomach juice. It isn't an approved drug anywhere, and it has never been through a large human trial.

People want it for tendon, ligament and muscle injuries, and for gut problems. Those uses come from animal studies, most of them from one research group in Croatia, plus a large and growing pile of personal reports.

What the evidence shows

The animal data is broad: faster tendon and ligament healing, repair of the gut lining, and new blood vessel growth in injured tissue. The human data is thin. There are small pilot studies and case series, and no published randomized controlled trial.

When the FDA's advisers reviewed it in July, they looked at one specific use, ulcerative colitis. The agency's own scientists recommended against adding it to the compounding list. The committee voted for it anyway.

How Goodmorrow handles it

We don't prescribe BPC-157 today, and we don't sell research-grade vials. When the FDA finalizes the rule, we'll prescribe it through a licensed 503A compounding pharmacy, after an exam, with a written plan that says how long you'll take it and how we'll judge whether it's working.

If you're dealing with an injury now, start with a proper diagnosis. Your clinician will tell you honestly whether anything we offer today makes sense, and refer you when an injury needs imaging or a specialist.

Before you take it

  • BPC-157 is prohibited in tested sport. If you compete, don't take it.
  • Vials sold online as research chemicals have no pharmacy standards behind them. Purity, dose and sterility are unknown.

Stacks that include it

Follow updates about BPC-157

Join the update list. This does not reserve a treatment or mean that future availability is assured.

What are you interested in?

We'll only use this to contact you about appointments, by phone, text or email. No health details needed here. See our privacy policy.

Questions people ask

Is BPC-157 legal in Texas?

It isn't a controlled substance, but licensed pharmacies can't compound it for patients until the FDA adds it to the list of bulk ingredients they're allowed to use. The July 2026 vote was a recommendation, not that final step.

When will BPC-157 be available at Goodmorrow?

As soon as the FDA publishes a final decision and a licensed pharmacy can fill it. The FDA isn't bound to follow its advisers, so there's no firm date. Join the list and we'll tell you the week it changes.

Can I take BPC-157 if I get drug tested?

Not if you compete in tested sport. It's on the World Anti-Doping Agency's prohibited list, and USADA has warned athletes about it specifically.

Sources

  1. FDA documentJuly 23-24, 2026 Meeting of the Pharmacy Compounding Advisory Committee U.S. Food and Drug Administration, July 2026
  2. Secondary sourceFDA Panel Votes to Loosen Restrictions for Four Peptides PharmExec, July 2026
  3. Secondary sourceFDA advisory committee nominates six peptides for pharmacies to compound National Community Pharmacists Association, July 31, 2026
  4. Secondary sourceThe legal status of BPC-157 in compounding and clinical practice Holt Law, August 2026
  5. Research publicationMultifunctionality and Possible Medical Application of the BPC 157 Peptide: Literature and Patent Review Pharmaceuticals (via PubMed Central), 2025
  6. Secondary sourceBPC-157: Experimental Peptide Creates Risk for Athletes USADA

Good days ahead.

Join the opening list for appointment updates.

Join the opening list